

24<sup>th</sup> January, 2025

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2024**

The Presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2024 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

Encl : A/a

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com



## Q3 FY 2024-25

Revenues: Summary



## Revenue: Summary

Revenues (Rs cr)	Q3 FY25	Q3 FY24	Gr%
India	1581	1415	12%
United States	271	274	-1%
Germany	282	270	4%
Brazil	291	312	-7%
Others	384	461	-16%
<b>Total</b>	<b>2809</b>	<b>2732</b>	<b>3%</b>



## Revenue: Summary

Revenues (Rs cr)	9M FY25	9M FY24	Gr%
India	4848	4286	13%
United States	798	815	-2%
Germany	853	795	7%
Brazil	750	754	-1%
Others	1308	1333	-2%
<b>Total</b>	<b>8557</b>	<b>7983</b>	<b>7%</b>

